Neoplasms, Germ Cell and Embryonal  >>  Torisel (temsirolimus)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

14 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Torisel (temsirolimus) / Pfizer
NCT00016328: CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme

Completed
2
33
US
temsirolimus, CCI-779, cell cycle inhibitor 779, Torisel, laboratory biomarker analysis, pharmacological study, pharmacological studies
National Cancer Institute (NCI)
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
08/05
 
NCT00022464: CCI-779 in Treating Patients With Metastatic Melanoma

Completed
2
US, Canada
temsirolimus
City of Hope Medical Center, National Cancer Institute (NCI)
Melanoma (Skin)
09/05
09/05
NCT00808899: Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma

Terminated
2
4
US
Temsirolimus, Irinotecan, Surgical Resection of Primary Tumor, Cyclophosphamide, Doxorubicin, Etoposide, Cisplatin, Topotecan, PBSC, Radiation Therapy, 13-cis-retinoic acid
St. Jude Children's Research Hospital
Neuroblastoma
07/09
07/09
NCT00800917 / 2008-003679-40: A Study of Temsirolimus and Bevacizumab in Recurrent Glioblastoma Multiforme

Completed
2
12
Europe
Temsirolimus, Bevacizumab
Rigshospitalet, Denmark, University of Copenhagen, Wyeth is now a wholly owned subsidiary of Pfizer, Roche, Copenhagen
Glioblastoma Multiforme
02/10
02/10
NCT00281957: Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery

Checkmark P2 data (Melanoma)
Jan 2012 - Jan 2012: P2 data (Melanoma)
Completed
2
109
US
sorafenib tosylate, BAY 43-9006, BAY 43-9006 Tosylate Salt, BAY 54-9085, Nexavar, SFN, tipifarnib, R115777, Zarnestra, temsirolimus, CCI-779, cell cycle inhibitor 779, Torisel
National Cancer Institute (NCI)
Recurrent Melanoma, Stage IV Melanoma
12/10
01/11
NCT00093782: Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma

Completed
2
36
Canada
temsirolimus, CCI-779, cell cycle inhibitor 779, Torisel, laboratory biomarker analysis
National Cancer Institute (NCI)
Metastatic Gastrointestinal Carcinoid Tumor, Pulmonary Carcinoid Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma
04/11
04/11
NCT01851408: Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

Withdrawn
2
0
US
sorafenib tosylate, BAY 43-9006, BAY 43-9006 Tosylate Salt, BAY 54-9085, Nexavar, SFN, temsirolimus, CCI-779, cell cycle inhibitor 779, Torisel
National Cancer Institute (NCI), M.D. Anderson Cancer Center
Melanoma, Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma
02/12
02/12
NCT01166126: Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV

Terminated
2
4
US
temsirolimus, CCI-779, cell cycle inhibitor 779, Torisel, selumetinib, ARRY-142886, AZD6244, laboratory biomarker analysis
National Cancer Institute (NCI)
Mucosal Melanoma, Recurrent Melanoma, Stage IV Melanoma
06/12
06/12
NCT00397982: Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma

Checkmark
Sep 2013 - Sep 2013: 
Checkmark
Apr 2013 - Apr 2013: 
Completed
2
17
US
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Laboratory Biomarker Analysis, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel, Therapeutic Conventional Surgery
National Cancer Institute (NCI), Fox Chase Cancer Center
Recurrent Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma
07/13
07/13
NCT01019434 / 2008-003003-31: Radiation Therapy and Temsirolimus or Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Completed
2
111
Europe
temozolomide, temsirolimus
European Organisation for Research and Treatment of Cancer - EORTC, Pfizer
Brain and Central Nervous System Tumors
12/13
03/14
NCT01614795: Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Completed
2
46
Canada, US
Cixutumumab, Anti-IGF-1R Recombinant Monoclonal Antibody IMC-A12, IMC-A12, Laboratory Biomarker Analysis, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel
National Cancer Institute (NCI)
Childhood Alveolar Soft Part Sarcoma, Childhood Angiosarcoma, Childhood Epithelioid Sarcoma, Childhood Fibrosarcoma, Childhood Gliosarcoma, Childhood Leiomyosarcoma, Childhood Liposarcoma, Childhood Malignant Peripheral Nerve Sheath Tumor, Childhood Synovial Sarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Osteosarcoma, Rhabdomyosarcoma
04/14
04/14
NCT01010126: Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Checkmark P2 data-ASCO
Jun 2012 - Jun 2012: P2 data-ASCO
Checkmark P2 data
More
Completed
2
252
Canada, US
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar FKB238, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel
National Cancer Institute (NCI)
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Endometrial Serous Adenocarcinoma, Localized Non-Resectable Adult Liver Carcinoma, Lung Carcinoid Tumor, Malignant Pancreatic Gastrinoma, Malignant Pancreatic Glucagonoma, Malignant Pancreatic Insulinoma, Malignant Pancreatic Somatostatinoma, Metastatic Digestive System Neuroendocrine Tumor G1, Ovarian Carcinosarcoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Surface Papillary Adenocarcinoma, Pancreatic Alpha Cell Adenoma, Pancreatic Beta Cell Adenoma, Pancreatic Delta Cell Adenoma, Pancreatic G-Cell Adenoma, Pancreatic Polypeptide Tumor, Recurrent Adult Liver Carcinoma, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Neuroendocrine Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Regional Digestive System Neuroendocrine Tumor G1, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIA Uterine Corpus Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIB Uterine Corpus Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IIIC Uterine Corpus Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Stage IVA Uterine Corpus Cancer, Stage IVB Uterine Corpus Cancer, Uterine Carcinosarcoma
03/17
03/17
NCT00335764: Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

Checkmark In combination with sorafenib for recurrent glioblastoma or gliosarcoma
Jun 2013 - Jun 2013: In combination with sorafenib for recurrent glioblastoma or gliosarcoma
Checkmark P1/2 data
Oct 2012 - Oct 2012: P1/2 data
Completed
1/2
92
US
sorafenib tosylate, BAY 43-9006, BAY 43-9006 Tosylate Salt, BAY 54-9085, Nexavar, SFN, erlotinib hydrochloride, CP-358,774, erlotinib, OSI-774, tipifarnib, R115777, Zarnestra, temsirolimus, CCI-779, cell cycle inhibitor 779, Torisel
National Cancer Institute (NCI)
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
02/10
09/12
NCT00329719: Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma

Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Checkmark P1/2 data
Oct 2012 - Oct 2012: P1/2 data
Checkmark P2 data
More
Completed
1/2
115
US
Conventional Surgery, Laboratory Biomarker Analysis, Sorafenib Tosylate, BAY 43-9006 Tosylate, BAY 54-9085, Nexavar, sorafenib, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel
National Cancer Institute (NCI)
Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
02/13
02/13

Download Options